keyword
MENU ▼
Read by QxMD icon Read
search

Nephrogenic systemic fibrosis

keyword
https://www.readbyqxmd.com/read/28712039/cutaneous-manifestations-of-scleroderma-and-scleroderma-like-disorders-a-comprehensive-review
#1
REVIEW
Caterina Ferreli, Giulia Gasparini, Aurora Parodi, Emanuele Cozzani, Franco Rongioletti, Laura Atzori
Scleroderma refers to an autoimmune connective tissue fibrosing disease, including three different subsets: localized scleroderma, limited cutaneous systemic sclerosis, and diffuse cutaneous systemic sclerosis with divergent patterns of organ involvement, autoantibody profiles, management, and prognostic implications. Although systemic sclerosis is considered the disease prototype that causes cutaneous sclerosis, there are many other conditions that can mimic and be confused with SSc. They can be classified into immune-mediated/inflammatory, immune-mediated/inflammatory with abnormal deposit (mucinoses), genetic, drug-induced and toxic, metabolic, panniculitis/vascular, and (para)neoplastic disorders according to clinico-pathological and pathogenetic correlations...
July 16, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28691526/non-enhanced-versus-low-dose-contrast-enhanced-renal-magnetic-resonance-angiography-at-7-t-a-feasibility-study
#2
Anja Laader, Karsten Beiderwellen, Oliver Kraff, Stefan Maderwald, Mark E Ladd, Michael Forsting, Lale Umutlu
Background Considering the currently reported association between a repetitive application and cumulative dosage of Gadolinium (Gd)-based contrast agents and Gd-deposition in brain tissue as well as the risk for the advent of nephrogenic systemic fibrosis (NSF), techniques allowing for a dose reduction become an important key aspect aside from non-enhanced magnetic resonance angiography (MRA) techniques. Thus, this study was focused on the reduction and/or complete omission of contrast agent for renal MRA at 7T...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28687012/value-of-quantitative-magnetic-resonance-imaging-t1-relaxometry-in-predicting-contrast-enhancement-in-glioblastoma-patients
#3
Elke Hattingen, Andreas Müeller, Alina Jurcoane, Burkhard Mädler, Philip Ditter, Hans Schild, Ulrich Herrlinger, Martin Glas, Sied Kebir
The repetitive usage of gadolinium-based contrast agents (GBCA) is critical for magnetic resonance imaging (MRI) evaluation of tumor burden in glioblastoma patients. It is also a crucial tool for determination of radiographical response to treatment. GBCA injection, however, comes with a 2.4% rate of adverse events including life-threatening conditions such as nephrogenic systemic fibrosis (NSF). Moreover, GBCA have been shown to be deposited in brain tissue of patients even with an intact blood-brain barrier (BBB)...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28680623/nephrogenic-systemic-fibrosis
#4
Abhilash Koratala, Vikrampal Bhatti
Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen in patients with renal dysfunction, commonly precipitated by administration of gadolinium contrast. There is no consistently successful treatment, but oral steroids, topical dovonex, extracorporeal photopheresis, and plasmapheresis have been tried [http://www.icnfdr.org/ Last accessed: 1/6/2017]. Avoidance of gadolinium in such patients is the key to prevention.
July 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28606036/scleroderma-like-disorders
#5
Amit Sharma
Scleroderma is a term used to describe diseases that involve hardening and tightening of the skin and the underlying subcutaneous connective tissue. It could be localized to skin and subcutaneous tissue, or may involve the internal organs too in systemic sclerosis. There are disorders that can cause hardening and tightening of skin and mimic scleroderma but are rarely associated with Raynaud phenomenon, sclerodactyly, and autoantibodies in the serum, features specific to scleroderma/systemic sclerosis. These are termed as "scleroderma variants" or "scleroderma like disorders"...
June 11, 2017: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/28540211/delayed-enhancement-cardiac-computed-tomography-for-the-assessment-of-myocardial-infarction-from-bench-to-bedside
#6
REVIEW
Gaston A Rodriguez-Granillo
A large number of studies support the increasingly relevant prognostic value of the presence and extent of delayed enhancement (DE), a surrogate marker of fibrosis, in diverse etiologies. Gadolinium and iodinated based contrast agents share similar kinetics, thus leading to comparable myocardial characterization with cardiac magnetic resonance (CMR) and cardiac computed tomography (CT) at both first-pass perfusion and DE imaging. We review the available evidence of DE imaging for the assessment of myocardial infarction (MI) using cardiac CT (CTDE), from animal to clinical studies, and from 16-slice CT to dual-energy CT systems (DECT)...
April 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/28501081/the-impact-of-excess-ligand-on-the-retention-of-nonionic-linear-gadolinium-based-contrast-agents-in-patients-with-various-levels-of-renal-dysfunction-a-review-and-simulation-analysis
#7
REVIEW
John P Prybylski, Michael Jay
The role of gadolinium (Gd)-based contrast agents (GBCAs) in the pathophysiology of nephrogenic systemic fibrosis (NSF) is now uncontested. Although the definitive mechanism has not been established, the association with weaker GBCA ligands and with reduced renal clearance supports a hypothesis that Gd release from the GBCAs is a key process in precipitating the disease. Prevention strategies often include the use of more stable GBCA ligands in patients with reduced kidney function, but animal models and some clinical data suggest that better patient outcomes can be achieved when excess ligand is administered with weaker GBCAs; this is particularly significant for OptiMARK, which contains a nonionic, linear ligand similar to gadodiamide, the active ingredient in Omniscan, but contains twice the amount of excess ligand...
May 2017: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/28501075/gadolinium-retention-and-toxicity-an-update
#8
REVIEW
Miguel Ramalho, Joana Ramalho, Lauren M Burke, Richard C Semelka
Until 2006, the main considerations regarding safety for all gadolinium-based contrast agents (GBCAs) were related to short-term adverse reactions. However, the administration of certain "high-risk" GBCAs to patients with renal failure resulted in multiple reported cases of nephrogenic systemic fibrosis. Findings have been reported regarding gadolinium deposition within the body and various reports of patients who report suffering from acute and chronic symptoms secondary to GBCA's exposure. At the present state of knowledge, it has been proved that gadolinium deposits also occur in the brain, irrespective of renal function and GBCAs stability class...
May 2017: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/28501073/prophylactic-hemodialysis-for-protection-against-gadolinium-induced-nephrogenic-systemic-fibrosis-a-doll-s-house
#9
EDITORIAL
Jerry Yee
No abstract text is available yet for this article.
May 2017: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/28473338/appropriate-minimal-dose-of-gadobutrol-for-3d-time-resolved-mra-of-the-supra-aortic-arteries-comparison-with-conventional-single-phase-high-resolution-3d-contrast-enhanced-mra
#10
S H Bak, H G Roh, W-J Moon, J W Choi, H S An
BACKGROUND AND PURPOSE: The development of nephrogenic systemic fibrosis and neural tissue deposition is gadolinium dose-dependent. The purpose of this study was to determine the appropriate minimal dose of gadobutrol with time-resolved MRA to assess supra-aortic arterial stenosis with contrast-enhanced MRA as a reference standard. MATERIALS AND METHODS: Four hundred sixty-two consecutive patients underwent both standard-dose contrast-enhanced MRA and low-dose time-resolved MRA and were classified into 3 groups; group A (a constant dose of 1 mL for time-resolved MRA), group B (2 mL), or group C (3 mL)...
May 4, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28387639/effect-of-intravenous-administration-of-contrast-media-on-serum-creatinine-levels-in-neonates
#11
Maria A Bedoya, Ammie M White, J Christopher Edgar, Madhura Pradhan, Elisabeth L Raab, James S Meyer
Purpose To assess the effect of intravenous contrast media on renal function in neonates. Materials and Methods Institutional review board approval was obtained with waiver of consent. Electronic health records from January 2011 to April 2013 were reviewed retrospectively. Measures of renal function were obtained in inpatient neonates who underwent magnetic resonance (MR) imaging or computed tomography (CT) and for whom serum creatinine (Cr) levels were obtained within 72 hours before imaging and at least one time after imaging (>1 day after administration of contrast material)...
August 2017: Radiology
https://www.readbyqxmd.com/read/28368880/critical-questions-regarding-gadolinium-deposition-in-the-brain-and-body-after-injections-of-the-gadolinium-based-contrast-agents-safety-and-clinical-recommendations-in-consideration-of-the-ema-s-pharmacovigilance-and-risk-assessment-committee-recommendation
#12
Val M Runge
For magnetic resonance, the established class of intravenous contrast media is the gadolinium-based contrast agents. In the 3 decades since initial approval, these have proven in general to be very safe for human administration. However, in 2006, a devastating late adverse reaction to administration of the less stable gadolinium-based contrast agents was identified, nephrogenic systemic fibrosis. The result of actions taken by the European Medicines Agency and the US Food and Drug Administration, stratifying the agents by risk and contraindicating specific agents in severe renal dysfunction, has led to no new cases being identified in North America or Europe...
June 2017: Investigative Radiology
https://www.readbyqxmd.com/read/28362042/gadolinium-contrast-agents-are-they-really-safe
#13
Hana Malikova, Michal Holesta
Gadolinium-based contrast agents (GBCA) are used worldwide for enhanced MRI examinations, including heart and vessels. Gadolinium is a highly toxic heavy metal. If used in GBCA it must be tightly bound to ligands. The configuration of ligands influences the stability of the GBCA and two types of chelates have been used. Macrocyclic chelates offer better protection and binding of gadolinium ion than linear chelates with a flexible open chain - gadolinium could be more easily released from the latter ones. GBCAs are excreted from the body mostly by the kidneys, which is of importance in chronic kidney disease...
March 28, 2017: Journal of Vascular Access
https://www.readbyqxmd.com/read/28323787/gadolinium-naive-nephrogenic-systemic-fibrosis-of-breast-mimicking-inflammatory-breast-carcinoma
#14
Pierre Halteh, Jing Huang, Horatio F Wildman, Cynthia M Magro
No abstract text is available yet for this article.
April 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28323657/histology-and-gadolinium-distribution-in-the-rodent-brain-after-the-administration-of-cumulative-high-doses-of-linear-and-macrocyclic-gadolinium-based-contrast-agents
#15
Jessica Lohrke, Anna-Lena Frisk, Thomas Frenzel, Laura Schöckel, Martin Rosenbruch, Gregor Jost, Diana Constanze Lenhard, Martin A Sieber, Volker Nischwitz, Astrid Küppers, Hubertus Pietsch
OBJECTIVES: Retrospective studies in patients with primary brain tumors or other central nervous system pathologies as well as postmortem studies have suggested that gadolinium (Gd) deposition occurs in the dentate nucleus (DN) and globus pallidus (GP) after multiple administrations of primarily linear Gd-based contrast agents (GBCAs). However, this deposition has not been associated with any adverse effects or histopathological alterations. The aim of this preclinical study was to systematically examine differences between linear and macrocyclic GBCAs in their potential to induce changes in brain and skin histology including Gd distribution in high spatial resolution...
June 2017: Investigative Radiology
https://www.readbyqxmd.com/read/28318680/nephrogenic-systemic-fibrosis-a-15-year-retrospective-study-at-a-single-tertiary-care-center
#16
Janice Wilson, Kristyna Gleghorn, Quincy Seigel, Brent Kelly
BACKGROUND: Despite multiple therapeutic approaches for nephrogenic systemic fibrosis (NSF), no single treatment has convincingly shown consistent benefit. The most successful outcomes have been associated with recovery of renal function, although evidence remains limited and past studies have been inconclusive. OBJECTIVE: We sought to investigate whether improvement of renal function via successful transplantation or via return of renal function after acute kidney injury correlates with improvement of NSF, and to further characterize the clinical features and progression of NSF...
August 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28292235/paramagnetic-and-superparamagnetic-inorganic-nanoparticles-for-t1-weighted-magnetic-resonance-imaging
#17
Leyong Zeng, Di Wu, Ruifen Zou, Tianxiang Chen, Jinchao Zhang, Aiguo Wu
Magnetic resonance imaging (MRI) has become a promising technique in the early diagnosis of cancers, especially the application of contrast agents can further enhance the detection limitation. Compared with the dark signal in "negative" contrast agents (T2), "positive" contrast agents (T1) with bright signal are more desirable for high-resolution imaging. However, the clinical used gadolinium complexes have short circulation time and the risk of nephrogenic system fibrosis. Therefore, to overcome the disadvantage of T2 agents and traditional T1 agents, it is very interesting to develop nano-scaled T1-weighted MRI contrast agents with safer and more precise imaging performance...
March 14, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28261636/safety-and-efficacy-of-a-high-performance-graphene-based-magnetic-resonance-imaging-contrast-agent-for-renal-abnormalities
#18
Shruti Kanakia, Jimmy Toussaint, Praveen Kukarni, Stephen Lee, Sayan Mullick Chowdhury, Slah Khan, Sandeep K Mallipattu, Kenneth R Shroyer, William Moore, Balaji Sitharaman
The etiology of renal insufficiency includes primary (e.g polycystic kidney disease) or secondary (e.g. contrast media, diabetes) causes. The regulatory restrictions placed on the use of contrast agents (CAs) for non-invasive imaging modalities such as X-ray computed tomography (CT) and magnetic resonance imaging (MRI) affects the clinical management of these patients. With the goal to develop a next-generation CA for unfettered use for renal MRI, here we report, in a rodent model of chronic kidney disease, the preclinical safety and efficacy of a novel nanoparticle CA comprising of manganese (Mn(2+)) ions intercalated graphene coated with dextran (hereafter called Mangradex)...
December 2016: Graphene Technol
https://www.readbyqxmd.com/read/28193901/exceedingly-small-iron-oxide-nanoparticles-as-positive-mri-contrast-agents
#19
He Wei, Oliver T Bruns, Michael G Kaul, Eric C Hansen, Mariya Barch, Agata Wiśniowska, Ou Chen, Yue Chen, Nan Li, Satoshi Okada, Jose M Cordero, Markus Heine, Christian T Farrar, Daniel M Montana, Gerhard Adam, Harald Ittrich, Alan Jasanoff, Peter Nielsen, Moungi G Bawendi
Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast...
February 28, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28110970/-plasma-exchange-in-nephrology-indications-and-technique
#20
Christophe Ridel, Sébastien Kissling, Laurent Mesnard, Alexandre Hertig, Éric Rondeau
Plasma exchange is a non-selective apheresis technique that can be performed by filtration or centrifugation allowing rapid purification of high molecular weight pathogens. An immunosuppressive treatment is generally associated to reduce the rebound effect of the purified substance. Substitution solutes such as human albumin and macromolecules are needed to compensate for plasma extraction. Compensation by viro-attenuated plasma is reserved solely for the treatment of thrombotic microangiopathies or when there is a risk of bleeding, because this product is very allergenic and expensive...
February 2017: Néphrologie & Thérapeutique
keyword
keyword
35934
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"